First Time Loading...

Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 12.45 USD 0.73% Market Closed
Updated: Apr 27, 2024

Entrada Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Entrada Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Entrada Therapeutics Inc
NASDAQ:TRDA
Operating Income
-$3.2m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Entrada Therapeutics Inc's Operating Income?
Operating Income
-3.2m USD

Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Operating Income amounts to -3.2m USD.

What is Entrada Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 3Y
51%

Over the last year, the Operating Income growth was 97%. The average annual Operating Income growth rates for Entrada Therapeutics Inc have been 51% over the past three years .